Procoagulant inhibitory properties of paclitaxel poliglumex

BACKGROUND: In Phase I evaluation of CT-2103 (paclitaxel poliglumex), prolongation of prothrombin time (PT) and activated thromboplastin time (aPTT) was observed, without clinical consequence, with doses 1.3–1.5 times higher than the current clinical dose of 175 mg/m(2). This Phase I, open-label, no...

Descripción completa

Detalles Bibliográficos
Autores principales: Nemunaitis, John, Senzer, Neil, Cooper, Barry, Nemunaitis, Michael, Bedell, Cynthia, Singer, Jack W, Oldham, Fred B
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056324/
https://www.ncbi.nlm.nih.gov/pubmed/21403785
http://dx.doi.org/10.2147/IJGM.S12170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3056324/
https://www.ncbi.nlm.nih.gov/pubmed/21403785
http://dx.doi.org/10.2147/IJGM.S12170

Ejemplares similares